.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Julphar
Teva
Harvard Business School
Moodys
Medtronic
UBS
Queensland Health
Chinese Patent Office
Cipla

Generated: December 16, 2017

DrugPatentWatch Database Preview

Cerexa Company Profile

« Back to Dashboard

What is the competitive landscape for CEREXA, and when can generic versions of CEREXA drugs launch?

CEREXA has two approved drugs.

There are thirteen US patents protecting CEREXA drugs.

There are two hundred and eleven patent family members on CEREXA drugs in fifty-eight countries and fourteen supplementary protection certificates in eleven countries.

Summary for Cerexa

International Patents:211
US Patents:13
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
CerexaAVYCAZavibactam sodium; ceftazidimePOWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
CerexaAVYCAZavibactam sodium; ceftazidimePOWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeYY► Subscribe
CerexaAVYCAZavibactam sodium; ceftazidimePOWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► SubscribeYY► Subscribe
CerexaAVYCAZavibactam sodium; ceftazidimePOWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
CerexaAVYCAZavibactam sodium; ceftazidimePOWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-001Oct 29, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
CerexaAVYCAZavibactam sodium; ceftazidimePOWDER;IV (INFUSION)206494-001Feb 25, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
CerexaTEFLAROceftaroline fosamilPOWDER;IV (INFUSION)200327-002Oct 29, 2010RXYesYes► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CEREXA drugs

Drugname Dosage Strength Tradename Submissiondate
ceftaroline fosamilInjection400 mg/vial and 600 mg/vialTEFLARO10/29/2014

Non-Orange Book Patents for Cerexa

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,638,529Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
8,829,191Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof► Subscribe
9,580,424Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
9,062,053Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt► Subscribe
7,732,610Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Cerexa Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2010096798► Subscribe
World Intellectual Property Organization (WIPO)2012172368► Subscribe
EcuadorSP12011739► Subscribe
New Zealand702479► Subscribe
France2835186► Subscribe
TunisiaSN04137► Subscribe
Portugal1307457► Subscribe
Cyprus1109276► Subscribe
South Africa201202924► Subscribe
China1679595► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Cerexa Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1043327/01Switzerland► SubscribePRODUCT NAME: CEFTAROLIN FOSAMIL; REGISTRATION NO/DATE: SWISSMEDIC 62672 29.08.2013
0568Netherlands► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
2Finland► Subscribe
90003-0Sweden► SubscribePRODUCT NAME: CEFTAROLINFOSAMIL; REG. NO/DATE: EU/1/12/785/001 20120823
0847Netherlands► SubscribePRODUCT NAME: FARMACEUTISCH MENGSEL OF SAMENSTEL DAT DE VOLGENDE WERKZAME BESTANDDELEN BEVAT: (1) CEFTAZIDIM OF EEN ZOUT ERVAN, EN (2) AVIBACTAM OF EEN ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/16/1109/001 20160628
C0008France► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL, SES ESTERS OU SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/785/001 20120823
00568Netherlands► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/12/785/001 00120823
2016037Lithuania► SubscribePRODUCT NAME: CEFTAZIDIMAS + AVIBAKTAMAS; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
134Luxembourg► SubscribePRODUCT NAME: CEFTAROLINE FOSAMIL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (ZINFORO)
2013 00003Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Julphar
Harvard Business School
Novartis
Teva
Healthtrust
US Department of Justice
McKesson
Deloitte
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot